These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19407109)

  • 1. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.
    Sundar S; Singh A; Agarwal D; Rai M; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2009 May; 80(5):700-3. PubMed ID: 19407109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
    Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
    Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
    Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B therapy in kala-azar.
    Giri OP
    J Indian Med Assoc; 1993 Apr; 91(4):91-3. PubMed ID: 8409490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
    Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
    J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study.
    Sundar S; Singh A; Rai M; Chakravarty J
    Am J Trop Med Hyg; 2015 Mar; 92(3):513-7. PubMed ID: 25510715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis.
    Syriopoulou V; Daikos GL; Theodoridou M; Pavlopoulou I; Manolaki AG; Sereti E; Karamboula A; Papathanasiou D; Krikos X; Saroglou G
    Clin Infect Dis; 2003 Mar; 36(5):560-6. PubMed ID: 12594635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
    Sundar S; Pandey K; Thakur CP; Jha TK; Das VN; Verma N; Lal CS; Verma D; Alam S; Das P
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3169. PubMed ID: 25233346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
    Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
    Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.